Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.

rosopatamab tetraxetan (ATL101) - Telix

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

rosopatamab-225Ac (CONV01-α) - Weill Cornell Medical College, Dominari Holdings

http://www.ncbi.nlm.nih.gov/pubmed/37424145

Ana Molina; Benedict Ho; Cora N Sternberg; David M Nanus; Jones T Nauseef; Joseph R Osborne; Joseph Thomas; Judith Stangl-Kremser; Michael Sun; Neil H Bander; Scott Tagawa

Jul 10, 2023